Kidney Stones

New findings from the PKIDS trial raise questions about the preference for ureteroscopy in clinical practice.

"What we showed was that there's no difference in the pressures whether you use CVAC or standard ureteroscopy," says Roger Sur, MD.

The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.

The code, 0991T, will become effective on January 1, 2026.

Khurshid R. Ghani, MBChB, MS, FRCS, discusses how results from the SOUL trial may shape clinical decision-making regarding stent placement.

The study compared patient experiences with silicone vs polyurethane ureteral stents.

“It is possible to conserve fluid when we're trying to do these procedures without compromising patient care," says Roshan M. Patel, MD.

"We...observed an exceedingly high degree of safety across the board, with very few complications,” says Jared S. Winoker, MD.

Jared S. Winoker, MD, addresses the wide range of stone burdens treated by the CVAC system for the study.

The risk of stricture formation was 4.6% in the TFL cohort vs 2.4% in the holmium laser cohort.

"There was a significant increase in overall fatigue after performing flexible ureteroscopy," says Sarah Razavi, MD.

Professor Andreas Skolarikos shares his experience with the LithoVue Elite System.

Joshua M. Heiman, MD, details key findings from the POuND OUT study.

John Michael DiBianco, MD, discusses findings from the BLUES trial.

Patient-reported pain scores were significantly improved with stent omission.

“We do not feel that our results undermine the importance of fluid intake for stone prevention," says Alana C. Desai, MD.

DiBianco discusses findings from the Better Lithotripsy and Ureteroscopy Evaluation of Stenting trial.

The SOUL study is assessing patient-reported outcomes and unplanned health care utilization among patients who had stent placement vs stent omission after ureteroscopy.

The investigators reported a median stone clearance of 96.44%.

New research links higher drinking water contaminants to increased kidney stone risk.

Data from the SOUND trial are intended to support submission for FDA 510(k) clearance of the Break Wave device.

“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM.

“You absolutely need to have a CT scan prior to the surgery to best identify and really intimately understand the kidney’s anatomy," says Perry Xu, MD.

Overall, 71% of patients had no fragment greater than 2 mm following treatment.

Ian Metzler, MD, discusses developments in imaging and treating stones.

“The benefit of being here at the University of Minnesota is that we have a bunch of different types of settings to be able to trial this," says Hailey Frye.

“The technology in the field of stone management is exciting, and I think it offers patients a lot more options than what they've had in the past,” says Brian Stork, MD.

“I think it's primarily due to dietary changes that are more and more prevalent regardless of sex,” says Ian Metzler, MD, MTM.

“I would say the take-home message for this study is that prescribing tamsulosin for a week prior to an anticipated surgery that involves flexible ureteroscopy is a very simple practice that certainly is within standard of care within pediatric urology," says Kate H. Kraft, MD, MHPE, FACS, FAAP.